Overview

A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors

Status:
Not yet recruiting
Trial end date:
2026-04-20
Target enrollment:
Participant gender:
Summary
This study will test how well a new medicine called concizumab works for participants who have haemophilia A or B with or without inhibitors. The purpose is to show that concizumab can prevent bleeds and is safe to use. Participants will have to inject the study medicine every day under the skin with a pen-injector. The study will last for about 2 years.
Phase:
Phase 3
Details
Lead Sponsor:
Novo Nordisk A/S